Evidence map›Paper›PMID 34783936›Full record

ArticleInternational journal of clinical oncology2022

Estimated tumor blood flow as a predictive imaging indicator of therapeutic response in pancreatic ductal adenocarcinoma: use of three-phase contrast-enhanced computed tomography.

Hiromitsu Maehira, Yoshihisa Tsuji, Hiroya Iida, Haruki Mori, Nobuhito Nitta, Takeru Maekawa, Sachiko Kaida, Toru Miyake, Masaji Tani

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hiromitsu MaehiraDepartment of Surgery, Shiga University of Medical Science, Shiga, Japan.
Yoshihisa TsujiDepartment of Community and General Medicine, Sapporo Medical University, Chuo-ku, Sapporo, Hokkaido, S1 W17060-8556, Japan. ytsuji@sapmed.ac.jp.
Hiroya IidaDepartment of Surgery, Shiga University of Medical Science, Shiga, Japan.
Haruki MoriDepartment of Surgery, Shiga University of Medical Science, Shiga, Japan.
Nobuhito NittaDepartment of Surgery, Shiga University of Medical Science, Shiga, Japan.
Takeru MaekawaDepartment of Surgery, Shiga University of Medical Science, Shiga, Japan.
Sachiko KaidaDepartment of Surgery, Shiga University of Medical Science, Shiga, Japan.
Toru MiyakeDepartment of Surgery, Shiga University of Medical Science, Shiga, Japan.
Masaji TaniDepartment of Surgery, Shiga University of Medical Science, Shiga, Japan.
Shiga University of Medical Science · JPSapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreoperative chemotherapy or chemoradiotherapy is a common strategy for treating pancreatic ductal adenocarcinoma (PDAC). This study aimed to assess the association between the therapeutic response in PDAC and tumor blood circulation.

methodsThe medical records of patients who underwent chemotherapy or chemoradiotherapy prior to pancreatectomy for PDAC were reviewed. Of these, patient data that included three-phase contrast-enhanced computed tomography (CECT) findings before treatments were used in this study. We evaluated the estimated tumor blood flow (eTBF) using CECT. According to the therapeutic histopathological response defined by the Evans classification, patients were divided into poor (grade I/IIa) and good (grade IIb/III/IV) responder groups. The variables, including eTBF, were compared between the two groups.

resultsThirty patients were enrolled in this study. Of these, 13 (43.3%) (grade IIB/III/IV: 8/4/1 patients) were categorized into the good responder group and 17 patients (56.7%) (grade I/IIA: 4/13 patients) were categorized into the poor responder group. eTBF was significantly higher in the good responder group (0.39 s

conclusionseTBF can be used to predict the therapeutic histopathological response in PDAC prior to treatment.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsChemoradiotherapyHumansPancreatectomyRetrospective StudiesTomography, X-Ray ComputedChemotherapyComputed tomographyImaging indicatorPancreatic cancerTherapeutic responseTumor blood flow

Identifiers

PMID34783936
OpenAlexW3214633589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.